Go Pro

Hims & Hers Health (HIMS) Stock Price, News & Analysis

Hims & Hers Health logo
$31.64 -0.52 (-1.60%)
Closing price 03:59 PM Eastern
Extended Trading
$31.62 -0.02 (-0.06%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Hims & Hers Health Stock (NYSE:HIMS)

Advanced

Key Stats

Today's Range
$31.13
$32.42
50-Day Range
$24.97
$38.34
52-Week Range
$13.74
$65.30
Volume
8.36 million shs
Average Volume
14.63 million shs
Market Capitalization
$7.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.43
Consensus Rating
Hold

Company Overview

Hims & Hers Health, Inc. is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support. Through secure online questionnaires and video visits, patients receive personalized treatment plans covering conditions such as erectile dysfunction, acne, hair thinning, anxiety and depression. Hims & Hers also distributes supplements, vitamin formulations and topical solutions designed to complement its prescription offerings.

Founded in 2017 by Andrew Dudum and headquartered in San Francisco, Hims & Hers emerged as one of the first telehealth subscriptions focused on consumer-friendly branding and straightforward access to care. In July 2021, the company completed a business combination with a special purpose acquisition company, enabling its public listing on the New York Stock Exchange under the ticker HIMS. Since its inception, Hims & Hers has pursued strategic partnerships and acquisitions to expand its medical and technological capabilities.

Serving customers across the continental U.S., Hims & Hers continues to develop its digital care model by enhancing telehealth platform features, broadening its therapeutic categories and strengthening clinical support. Under the leadership of CEO Andrew Dudum and a team of healthcare and technology executives, the company aims to reduce barriers to medical access while driving scalable growth in the evolving virtual care market.

AI Generated. May Contain Errors.

Hims & Hers Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

HIMS MarketRank™: 

Hims & Hers Health scored higher than 44% of companies evaluated by MarketBeat, and ranked 587th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.19, and is based on no strong buy ratings, 4 buy ratings, 11 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Hims & Hers Health is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Hims & Hers Health has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Hims & Hers Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Hims & Hers Health are expected to grow by 1,633.33% in the coming year, from $0.03 to $0.52 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hims & Hers Health is -351.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hims & Hers Health is -351.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Hims & Hers Health has a PEG Ratio of 90.51. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Hims & Hers Health has a P/B Ratio of 13.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Hims & Hers Health's valuation and earnings.
  • Percentage of Shares Shorted

    30.07% of the float of Hims & Hers Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 4.52.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently increased by 0.40%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Hims & Hers Health does not currently pay a dividend.

  • Dividend Growth

    Hims & Hers Health does not have a long track record of dividend growth.

  • News Sentiment

    Hims & Hers Health has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 27 news articles for Hims & Hers Health this week, compared to 9 articles on an average week.
  • Search Interest

    96 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 12% compared to the previous 30 days.
  • MarketBeat Follows

    25 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 92% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hims & Hers Health insiders have sold 131.20% more of their company's stock than they have bought. Specifically, they have bought $1,172,732.00 in company stock and sold $2,711,339.00 in company stock.

  • Percentage Held by Insiders

    11.76% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Hims & Hers Health's insider trading history.
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HIMS Stock News Headlines

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
Hims & Hers Health logo with a two-toned teal and coral capsule pill on a matching gradient background.
The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic
Hims & Hers Health shares have rallied despite an FTC lawsuit over data sharing and billing practices, as weight-loss drug partnerships and Wall Street's cautious Hold rating shape the stock's outlook ahead of Q2 earnings.
Bear statue on a trading desk surrounded by red downward stock charts on multiple monitors in a trading floor.
Bearish Pressure Is Building Around These 3 Stocks
Hims & Hers Health and QXO face heavy short interest amid dilution and loss concerns, while KLA has slid nearly 40% since June as AI-driven chip spending fears grip semiconductor stocks.
Hims and Hers Health logo displayed alongside branded personal care product bottles on bathroom countertops.
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.
Hims & Hers Health (NYSE:HIMS) CFO Sells 7,163 Shares
See More Headlines

HIMS Stock Analysis - Frequently Asked Questions

Hims & Hers Health's stock was trading at $32.45 on January 1st, 2026. Since then, HIMS shares have decreased by 2.5% and is now trading at $31.6450.

Hims & Hers Health, Inc. (NYSE:HIMS) posted its quarterly earnings data on Monday, May, 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.44. The business's revenue for the quarter was up 3.8% on a year-over-year basis.
Read the conference call transcript
.

Hims & Hers Health's Board of Directors approved a share repurchase program on Monday, November 17th 2025, which permits the company to buy back $250,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 3% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board believes its shares are undervalued.

Hims & Hers Health's top institutional shareholders include Handelsbanken Fonder AB (0.03%), Stonekeep Investments LLC (0.01%), FNY Investment Advisers LLC and Valeo Financial Advisors LLC. Insiders that own company stock include Melissa Baird, Michael Chi, Soleil Boughton, Oluyemi Okupe, David B Wells, Patrick Harrison Carroll, Christopher D Payne, Andrew Dudum, Garcia Andrea G Perez, Christiane Pendarvis, Irene Becklund, Irene Becklund, Deborah M Autor, Anja Manuel and Lynne Chou O'keefe.
View institutional ownership trends
.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/11/2026
Today
8/05/2026
Next Earnings (Estimated)
8/10/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NYSE:HIMS
CIK
1773751
Fax
N/A
Employees
2,442
Year Founded
2017

Price Target and Rating

High Price Target
$60.00
Low Price Target
$21.00
Potential Upside/Downside
-0.7%
Consensus Rating
Hold
Rating Score (0-4)
2.19
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
1,054.83
P/E Growth
90.51
Net Income
$128.37 million
Net Margins
-0.56%
Pretax Margin
-1.61%
Return on Equity
6.10%
Return on Assets
1.52%

Debt

Debt-to-Equity Ratio
2.18
Current Ratio
1.69
Quick Ratio
1.56

Sales & Book Value

Annual Sales
$2.35 billion
Price / Sales
3.12
Cash Flow
$0.82 per share
Price / Cash Flow
38.43
Book Value
$2.38 per share
Price / Book
13.30

Miscellaneous

Outstanding Shares
231,460,000
Free Float
204,239,000
Market Cap
$7.32 billion
Optionable
Optionable
Beta
2.40

Social Links

The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NYSE:HIMS) was last updated on 8/5/2026 by MarketBeat.com Staff.
From Our Partners